Kangstem Biotech selected by ‘F1000Prime’ for its publication about rheumatoid arthritis

Published: 2017-05-11 14:00:53

Updated: 2017-05-11 14:01:07

Kangstem Biotech announced on the 8^th that a paper about ‘Furestem-RA,’a rheumatoid arthritis stem cell treatment being developed by the company, was selected as an excellent paper by ‘Faculty of 1000 Prime(hereinafter referring to F1000Prime),’ a British online paper search system.

F1000Prime selects a paper from publications every month by thousands of senior scientists and leader experts in...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.